73 related articles for article (PubMed ID: 20605506)
1. [Tolerance of normal tissues to radiation therapy: ear].
Fleury B; Lapeyre M
Cancer Radiother; 2010 Jul; 14(4-5):284-9. PubMed ID: 20605506
[TBL] [Abstract][Full Text] [Related]
2. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients.
Pan CC; Eisbruch A; Lee JS; Snorrason RM; Ten Haken RK; Kileny PR
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1393-402. PubMed ID: 15817342
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
6. Effects of radiation on hearing in patients with malignancies of head and neck.
Balraj A; Raman R; Rangad F
Singapore Med J; 1992 Oct; 33(5):481-3. PubMed ID: 1455273
[TBL] [Abstract][Full Text] [Related]
7. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
[TBL] [Abstract][Full Text] [Related]
8. Radiation dose to otologic structures during head and neck cancer radiation therapy.
Ondrey FG; Greig JR; Herscher L
Laryngoscope; 2000 Feb; 110(2 Pt 1):217-21. PubMed ID: 10680919
[TBL] [Abstract][Full Text] [Related]
9. Ototoxicity after radiotherapy for head and neck tumors.
Bhandare N; Antonelli PJ; Morris CG; Malayapa RS; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):469-79. PubMed ID: 17236969
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.
Zuur CL; Simis YJ; Lamers EA; Hart AA; Dreschler WA; Balm AJ; Rasch CR
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):490-6. PubMed ID: 19135315
[TBL] [Abstract][Full Text] [Related]
11. [Damage to inner ear function caused by the effect of ionizing rays].
Strohm M; Ahlemann LM; Böhringer WK
HNO; 1985 Jan; 33(1):26-9. PubMed ID: 3972645
[TBL] [Abstract][Full Text] [Related]
12. A prospective study on radiation-induced changes in hearing function.
Herrmann F; Dörr W; Müller R; Herrmann T
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1338-44. PubMed ID: 16863923
[TBL] [Abstract][Full Text] [Related]
13. Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Kirwan J; Mendenhall WM
Laryngoscope; 2009 Oct; 119(10):1966-74. PubMed ID: 19688858
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
15. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated vs. conformal radiotherapy of parotid gland tumors: potential impact on hearing loss.
Lamers-Kuijper E; Schwarz M; Rasch C; Mijnheer B
Med Dosim; 2007; 32(4):237-45. PubMed ID: 17980823
[TBL] [Abstract][Full Text] [Related]
17. Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT).
Studer G; Studer SP; Zwahlen RA; Huguenin P; Grätz KW; Lütolf UM; Glanzmann C
Strahlenther Onkol; 2006 May; 182(5):283-8. PubMed ID: 16673062
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous therapy with high-dose cisplatin and radiation for unresectable squamous cell cancer of the head and neck: a phase I-II study.
Wheeler R; Salter M; Stephens S; Hardy I; Peters G; Urist M; Maddox W
NCI Monogr; 1988; (6):339-41. PubMed ID: 3352778
[TBL] [Abstract][Full Text] [Related]
19. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.
Bussels B; Maes A; Hermans R; Nuyts S; Weltens C; Van den Bogaert W
Radiother Oncol; 2004 Aug; 72(2):119-27. PubMed ID: 15297131
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
